Teleflex stock highlights Q2 EPS beat and 2026 guidance
Published on 10/07/2026 at 06:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teleflex stock (ISIN US8793691069) was trading at USD 125.24 on the NYSE on October 5, 2026 at 4:00 p.m. ET, up 0.90 percent on the session. The company entered the latest coverage cycle after reporting adjusted Q2 2026 EPS of USD 1.76 against consensus of USD 1.28, according to MarketBeat in its October 6, 2026 report.
Q2 revenue clears expectations
Teleflex generated USD 570.33 million in Q2 2026 revenue, exceeding the USD 559.59 million analyst estimate and increasing 28.9 percent from the prior-year quarter, MarketBeat reported on October 6, 2026. The comparison combines a clear earnings beat with substantial reported sales growth, but it also sets a demanding base for the second half.
The company raised its fiscal 2026 adjusted EPS guidance to USD 6.90-7.20 from USD 6.25-6.55. In the Yahoo Finance transcript dated August 6, 2026, management also reduced pro forma adjusted constant-currency revenue growth guidance to 3.5-4.5 percent from 4.5-5.5 percent.
Interventional integration remains the swing factor
Management said the interventional business produced USD 211.9 million of Q2 revenue, down 1 percent year over year, while Vascular revenue increased 8 percent to USD 246.3 million and Surgical revenue rose 9.2 percent to USD 112.1 million, according to the August 6, 2026 earnings-call transcript. The contrast explains why higher EPS guidance coexists with a lower revenue-growth range.
Teleflex also expects its adjusted operating margin to remain near 19 percent in fiscal 2026, while management described a 23 percent steady-state margin profile after stranded costs are addressed. The company is using divestiture proceeds for debt reduction and share repurchases, with the stated plan including USD 800 million of debt reduction and a USD 1 billion repurchase authorization.
Consensus target stays above the stock
MarketBeat reported on October 6, 2026 that 12 analysts assigned Teleflex a Moderate Buy consensus, with five Buy ratings, four Holds, two Strong Buys and one Sell. The average 12-month price target was USD 155.20, which lies 23.9 percent above the USD 125.24 stock price.
Bank of America upgraded Teleflex from Neutral to Buy and lifted its target from USD 145.00 to USD 158.00 in a September 28, 2026 report published through MarketBeat. The analyst backdrop therefore reflects both the Q2 earnings beat and the execution risk tied to the interventional integration.
Teleflex stock trades below yearly high
Teleflex stock was trading at USD 125.24 on October 5, 2026, against a 52-week range of USD 100.18 to USD 145.00. Its market capitalization was USD 5.54 billion on that date, giving investors a market-value reference alongside the earnings and guidance changes.
Teleflex stock at a glance
- Company: Teleflex Incorporated
- ISIN: US8793691069
- Ticker: TFX
- Trading venue: NYSE
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 125.24
- Market capitalization: USD 5.54 billion (as of October 5, 2026)
- 52-week range: USD 100.18-145.00 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
